2021 Pharmaceuticals Research Review

2021 Pharmaceuticals Research Review

Report Highlights:

- The global market for generic drugs should grow from $411.6 billion in 2020 to $650.3 billion by 2025, at compound annual growth rate (CAGR) of 9.6% for the period of 2020-2025.
- The global market for orphan drugs should grow from $190.8 billion in 2021 to $248.2 billion by 2026, at compound annual growth rate (CAGR) of 5.4% for the period of 2021-2026.
- The global market for oncology pharmaceuticals should grow from $177.4 billion in 2021 to $313.7 billion by 2026, at compound annual growth rate (CAGR) of 12.1% for the period of 2021-2026.

The world pharmaceutical market was worth an estimated $1.2 trillion at ex-factory prices in 2020. It is one of the top performing industries globally. New medications are constantly being developed, approved and marketed, resulting in significant market growth. The FDA approved 55 novel drugs in 2021. Other market growth drivers include the aging population, as seniors use more medicines per capita and there is a rise in the prevalence and treatment of chronic diseases. Immunology, oncology and neurology are the fastest-growing therapy areas and are expected to be the main sources of growth through 2026. The biologics market is growing at significant rate and is expected to continue outstripping that of small molecules in coming decade. The three largest biologic therapy areas include oncology, autoimmune and diabetes.

The U.S. dominates the global pharmaceutical markets, accounting for almost half of pharmaceutical sales globally in 2021. However, the industry faces many challenges including regulatory hurdles, escalating R&D costs, and competition from generic drugs and biosimilars. The pharmaceutical industry, one of the most profitable industries in the world, is under significant pressure to bring in cost-effective and innovative drugs. The discipline of precision medicine and genomic medicine has gained significant interest from researchers and healthcare providers globally. Already, it is making an impact in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious disease, and its popularity is expected to grow significantly in coming years. Sensing the huge opportunity in the field of precision medicine and genomic medicine, several big pharma companies have been making huge investments to expand their precision and genomic medicine portfolios and pipelines. The number of personalized drugs is expected to double or even triple in the upcoming years.

This Pharmaceutical Research Review provides a sampling of the type of quantitative market information, analysis and guidance that has been aiding business decision making since the inception of BCC Research in 1971. It includes the highlights of reports published in late 2020 and 2021 on the following markets -
- PHM009J Global Markets for Generic Drugs
- PHM038F Global Markets for Orphan Drugs
- PHM256A Global Oncology Pharmaceutical Market
- PHM249A Immunotherapy Drugs: Global Markets
- PHM061E Global Markets for Infectious Disease Treatments
- PHM237A Pharmaceutical Treatments for Mental Health Disorders: Global Markets
- PHM010L Excipients in Pharmaceuticals: Global Markets to 2026
- PHM244A Softgel Capsules: Global Markets
- PHM043H Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging
- PHM248A Pharma 4.0 Market
- PHM149B Neurostimulation: Technologies and Global Markets

We hope you find this Research Review valuable, and we look forward to serving our customers’ pharmaceutical market research needs.